(Q37890469)

24 August 2017

0 references

1 reference

title

Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis (English)

1 reference

24 August 2017

0 references

B Singer

1

1 reference

24 August 2017

A P Ross

series ordinal

2

1 reference

24 August 2017

K Tobias

series ordinal

3

1 reference

24 August 2017

publication date

16 June 2011

1 reference

International Journal of Clinical Practice

24 August 2017

published in

1 reference

24 August 2017

volume

65

1 reference

24 August 2017

issue

8

1 reference

24 August 2017

page(s)

887-895

1 reference

24 August 2017

cites work

Demyelinating diseases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Overview of FTY720 clinical pharmacokinetics and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Clinical importance of the cytochromes P450

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Self-injection anxiety training: a treatment for patients unable to self-inject injectable medications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02721.X

10.1111/J.1742-1241.2011.02721.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference